

- R5 and R6 independently of one another are a (C₁-C₆)alkyl, aryl-(C₁-C₆)alkyl or aryl group, the said group optionally being substituted by one or more halogen atoms.

In another aspect, there is provided a compound of general formula (I) as disclosed herein for use as a drug.

In another aspect, there is provided a compound of general formula (I) as disclosed herein for use in the treatment or prevention of ~~cancer and chemotherapy-resistant cancer~~.

In another aspect, there is provided a pharmaceutical composition comprising at least one compound of general formula (I) as disclosed herein, in association with one or more pharmaceutically acceptable excipients.

In another aspect, there is provided a pharmaceutical composition comprising:


- (i) at least one formula (I) compound as disclosed herein; and
- (ii) at least one other active ingredient such as an anticancer agent,

as combination products for simultaneous, separate or time-staggered use thereof.


In another aspect, there is provided a pharmaceutical composition as disclosed herein for use as a drug intended to treat or prevent ~~cancer, in particular to treat a chemotherapy-resistant cancer~~.

In another aspect, there is provided a method for preparing a compound of formula (I) as disclosed herein, the method comprising the following successive steps:

- a) reacting an amine of following formula (II):



where X, R1, R2, R3, R4 and Ar are as defined above, R1 not representing a hydrogen atom,



8. A compound of general formula (I) according to any one of claims 1 to 7 for use as a drug.

9. A compound of general formula (I) according to any one of claims 1 to 7 for use in the treatment or prevention of cancer and chemotherapy-resistant cancer.

such as picropodophyllin; tetracarcin derivatives such as tetrocarcin A; corticosteroids such as prednisone; antibodies such as trastuzumab (anti-HER2 antibody), rituximab (anti-CD20 antibody), gemtuzamab, cetuximab, pertuzumab and bevacizumab; antagonists or selective modulators of oestrogen receptors such as tamoxifen, fulvestrant, toremifene, droloxifene, faslodex and raloxifene; aromatase inhibitors such as exemestane, anastrozole, letrozole and vorozole; differentiating agents such as retinoids e.g. retinoic acid and vitamin D and agents blocking the metabolism of retinoic acid such as accutane; DNA methyl-transferase inhibitors such as azacytidine and decitabine; antifolates such as perimetrex disodium; antibiotics such as actinomycin D, bleomycin, mitomycin C, actinomycin D, carminomycin, daunomycin and plicamycin; antimetabolites such as chlofarabine, aminopterin, cytosine arabinoside, floxuridine and methotrexate; apoptosis-inducing agents and anti-angiogenic agents of Bcl-2 inhibitors such as YC 137, BH 312, ABT 737, gossypol, HA 14-1, TW 37 and decanoic acid; agents binding to tubulin such as combrestatin, colchicine derivatives and nocodazole; kinase inhibitors such as flavoperidol, imatinib mesylate, erlotinib and gefitinib; farnesyl transferase inhibitors such as tipifarnib; histone-deacetylase inhibitors such as sodium butyrate, suberoylanilide hydroxamic acid, depsipeptide, NVP- LAQ824, R306465, JNJ-26481585 and trichostatin A; inhibitors of the ubiquitin-proteasome system such as MLN .41, bortezomib and yondelis; and telomerase inhibitors such as telomestatin.

15. The pharmaceutical composition according to any one of claims 10 to 14 for use as a drug intended to treat or prevent cancer, ~~in particular to treat a chemotherapy-resistant cancer.~~

16. A method for preparing a formula (I) compound according to any one of claims 1 to 7 comprising the following successive steps:

a) reacting an amine of following formula (II):